Biotech Stocks

Roth Capital Maintains Buy On Lannett, But More Cautious On Shares

In a research report issued today, Roth Capital analyst Scott Henry maintained coverage with a Buy rating on shares of Lannett Company (LCI) and $45 price target. The report follows Tuesday’s news …

Maxim Reaffirms Buy On Inovio Pharmaceuticals Ahead Of VGX-3100 Phase 2 Trial Results

In a research report issued yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Inovio Pharmaceuticals (INO) with an $18 price target, …

La Jolla Pharmaceutical: We Still Believe The Stock Is Undervalued, Says Wedbush

In a research report released yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform on La Jolla Pharmaceutical (LJPC) with a $45 price target, …

William Blair Maintains Outperform On Intuitive Surgical Ahead Of Upcoming 2Q14 Results

In a research note released yesterday, William Blair analyst Ben Andrew maintained an Outperform rating on Intuitive Surgical (ISRG) ahead of the upcoming …

Alcobra: No Raise Ahead Of Data – Strong Signal To Investors, Says Canaccord

In a research note published yesterday, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on Alcobra (ADHD), and a $40 price target, …

With Peregrine Being A Pivotal Stage Company, We View The Risk/Reward Profile As Favorable, Says Roth Capital

In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Peregrine Pharmaceuticals, Inc. (PPHM) and a $5 price target.

William Blair Maintaines Outperform On Salix Following Positive FDA Guidance For Relistor Appeal

In a research report issued yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (SLXP) with a $157 price target, following a …

H.C. Wainwright Initiates Buy On Epizyme; Sees 30% Upside For Stock

In a research note released this morning, H.C.

William Blair Reaffirms Outperform On Abbot Following The Sale Of Generic Drugs Business

In a research note issued yesterday, William Blair analyst Ben Andrew reaffirmed an Outperform rating on Abbott Laboratories (ABT). The report followsyesterday’s news that Abbott will …

William Blair Reiterates Outperform On Exelixis Following Positive Phase 3 Results

In a research report released yesterday, William Blair analyst John Sonnier reiterated an Outperform rating on Exelixis Inc (EXEL). The report follows yesterday’s news of positive …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts